Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, thirteen have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $38.5882.

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada boosted their price objective on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Tudor Pickering set a $23.00 target price on Dyne Therapeutics in a research report on Tuesday, December 9th. Evercore ISI reiterated an “outperform” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a report on Thursday, November 6th. Finally, Robert W. Baird set a $30.00 price objective on Dyne Therapeutics in a research note on Monday, December 8th.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently modified their holdings of the company. CWM LLC raised its stake in shares of Dyne Therapeutics by 168.1% during the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after acquiring an additional 1,900 shares in the last quarter. Chung Wu Investment Group LLC acquired a new position in shares of Dyne Therapeutics during the third quarter worth $30,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after purchasing an additional 2,446 shares during the last quarter. Quarry LP purchased a new stake in shares of Dyne Therapeutics during the 1st quarter valued at $47,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after purchasing an additional 1,109 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Price Performance

DYN opened at $19.27 on Monday. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -5.27 and a beta of 1.30. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. Dyne Therapeutics has a 12-month low of $6.36 and a 12-month high of $26.69. The business’s fifty day simple moving average is $19.17 and its 200-day simple moving average is $14.30.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.05. On average, equities research analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.